Investor Presentaiton
20
20
Symphony
"Proliferative Bioscaffold" for use in patients with severely impaired healing such
as Diabetic Foot Ulcers & Venous Leg Ulcers in the outpatient wound care center setting
Optimized structure
Gentle procesing conserves structure,
function and angioconduction
Better cell access
Porous architecture, perforations,
multiple layers and high surface
area support rapid cell migration
into a high volume graft to
accelerate tissue formation
High Aroa ECM Dose
Higher level of collagen and secondary
molecules compared to EpiFix and
OaSIS
Hyaluronic acid
- maintains wound
moisture
- synergistically promotes
angioconduction &
vascularisation
- encourages granulation
and epithelial migration
leading to closure
Less inflammation
Acellular so reduced inflammatory
response
FDA Clearance:
30 July, 2020
AROA™View entire presentation